logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2019
Aptinyx Inc
Data from Phase 2 study of NYX-783
Post-traumatic stress disorder (PTSD)
2H 2019
Neon Therapeutics, Inc.
52-week data from phase Ib trial of NEO-PV-01 ( NT-002)
Metastatic Non-Small Cell Lung Cancer
2H 2019
Tricida, Inc.
Submission of NDA for TRC101
Metabolic acidosis
2H 2019
Iterum Therapeutics plc
Top-line results from phase III trial of oral sulopenem etzadroxil combined with probenecid in a bilayer tablet (oral sulopenem) (SURE1)
uncomplicated urinary tract infections (uUTI) in women
2H 2019
Iterum Therapeutics plc
Top-line results from phase III trial of IV sulopenem followed by oral sulopenem etzadroxil combined with oral sulopenem (SURE2)
complicated urinary tract infections (cUTI) in adults
2H 2019
Iterum Therapeutics plc
Top-line results from phase III trial of IV sulopenem followed by oral sulopenem (SURE3)
complicated intra-abdominal infections (cIAI) in adults
2H 2019
Clementia Pharmaceuticals Inc.
Submission of NDA for Palovarotene
prevention of heterotopic ossification (HO) associated with flare ups of FOP
2H 2019
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III CMS trial of Firdapse
Congenital myasthenic syndromes (CMS)
2H 2019
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III MuSK-MG trial of Firdapse
Myasthenia gravis patients with autoantibodies to muscle-specific tyrosine kinase (MuSK)
Q3 2019
CONCERT PHARMACEUTICALS, INC.
Results from complete Phase 2a trial of CTP-543
Moderate-to-severe alopecia areata
2H 2019
Onconova Therapeutics, Inc
Top-line data from phase III pivotal trial of intravenous Rigosertib (INSPIRE)
Myelodysplastic Syndromes
2H 2019
Celyad SA
Topline data from phase I trial of CYAD-101, administered concurrently with FOLFOX chemotherapy (alloSHRINK)
Unresectable metastatic colorectal cancer
Q3 2019
Aridis Pharmaceuticals Inc
Top-line results from phase II trial of AR-105
Acute pneumonia caused by P. aeruginosa infection
2H 2019
Neurotrope, Inc.
Data from confirmatory phase II trial of Bryostatin-1
Moderate-to-severe Alzheimer's disease
2H 2019
Spectrum Pharmaceuticals Inc
Topline data from phase II study of Poziotinib (ZENITH20)
NSCLC patients with EGFR or HER2 exon 20 insertion mutations
2H 2019
La Jolla Pharmaceutical Co
Topline results from phase II study of LJPC-401
Hereditary Hemochromatosis
2H 2019
Transgenomic Inc.
Interim data from phase I/II clinical trial of MRT5005
Cystic fibrosis
2H 2019
Gritstone Oncology, Inc.
Preliminary efficacy data from phase I portion of GO-004
Metastatic lung, gastric, colorectal and bladder cancers
2H 2019
Unity Biotechnology, Inc.
Filing of IND application for UBX1967
Age-Related Diseases of the Eye
Q3 2019
Audentes Therapeutics, Inc.
Filing of IND for AT845
Pompe disease
2H 2019
Biomarin Pharmaceutical Inc.
Submission of BLA for Valoctocogene roxaparvovec
Hemophilia A patients
2H 2019
Biomarin Pharmaceutical Inc.
Filing of IND for BMN 30
Phenylketonuria
2H 2019
ASLAN Pharmaceuticals
Topline data from pivotal study comparing Varlitinib and capecitabine to placebo and capecitabine (TreeTopp)
Second-line biliary tract cancer
2H 2019
Microbot Medical Inc.
Data from a follow-up study of Self-Cleaning Shunt in vitro  and in-vivo models
Hydrocephalus, also known as "water in the brain"
2H 2019
Vaccinex, Inc.
Data from phase Ib/II combination study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab (CLASSICAL - Lung)
Non-small cell lung cancer patients